

Hideki Kawanishi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2972914/publications.pdf>

Version: 2024-02-01

100
papers

2,092
citations

279798

23
h-index

265206

42
g-index

101
all docs

101
docs citations

101
times ranked

1364
citing authors

#	ARTICLE	IF	CITATIONS
1	Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. <i>American Journal of Kidney Diseases</i> , 2004, 44, 729-37.	1.9	165
2	Recommendations on the Management of Encapsulating Peritoneal Sclerosis in Japan, 2005: Diagnosis, Predictive Markers, Treatment, and Preventive Measures. <i>Peritoneal Dialysis International</i> , 2005, 25, 83-95.	2.3	141
3	International Differences in the Location and Use of Arteriovenous Accesses Created for Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2018, 71, 469-478.	1.9	121
4	Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis – Position Paper for ISPD: 2017 Update. <i>Peritoneal Dialysis International</i> , 2017, 37, 362-374.	2.3	113
5	The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): Unifying Efforts to Inform Practice and Improve Global Outcomes in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2016, 36, 297-307.	2.3	107
6	Encapsulating Peritoneal Sclerosis in the Era of a Multi-Disciplinary Approach Based on Biocompatible Solutions: The Next-Pd Study. <i>Peritoneal Dialysis International</i> , 2014, 34, 766-774.	2.3	101
7	Japanese Society for Dialysis Therapy Clinical Guideline for Maintenance Hemodialysis Prescriptions: Therapeutic Apheresis and Dialysis, 2015, 19, 67-92.	0.9	88
8	Standard on Microbiological Management of Fluids for Hemodialysis and Related Therapies by the Japanese Society for Dialysis Therapy 2008. <i>Therapeutic Apheresis and Dialysis</i> , 2009, 13, 161-166.	0.9	81
9	Classification of Uremic Toxins and Their Role in Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1918-1928.	4.5	74
10	Burden of Kidney Disease, Health-Related Quality of Life, and Employment Among Patients Receiving Peritoneal Dialysis and In-Center Hemodialysis: Findings From the DOPPS Program. <i>American Journal of Kidney Diseases</i> , 2021, 78, 489-500.e1.	1.9	58
11	Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2325.	7.4	55
12	Combination Therapy with Peritoneal Dialysis and Hemodialysis. <i>Peritoneal Dialysis International</i> , 2006, 26, 150-154.	2.3	48
13	Successful surgical management of encapsulating peritoneal sclerosis. <i>Peritoneal Dialysis International</i> , 2005, 25 Suppl 4, S39-47.	2.3	38
14	Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2006, 22, 60-4.	0.1	33
15	Encapsulating peritoneal sclerosis (Review Article). <i>Nephrology</i> , 2005, 10, 249-255.	1.6	30
16	International Comparisons of Native Arteriovenous Fistula Patency and Time to Becoming Catheter-Free: Findings From the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2021, 77, 245-254.	1.9	30
17	Variation in Peritoneal Dialysis-Related Peritonitis Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). <i>American Journal of Kidney Diseases</i> , 2022, 79, 45-55.e1.	1.9	30
18	Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis – International Results from PDOPPS. <i>Kidney International Reports</i> , 2021, 6, 313-324.	0.8	29

#	ARTICLE	IF	CITATIONS
19	The New Standard of Fluids for Hemodialysis in Japan. Blood Purification, 2009, 27, 5-10.	1.8	28
20	Encapsulating Peritoneal Sclerosis—Medical and Surgical Treatment. Peritoneal Dialysis International, 2009, 29, 211-214.	2.3	27
21	2016 update Japanese Society for Dialysis Therapy Standard of fluids for hemodialysis and related therapies. Renal Replacement Therapy, 2018, 4, .	0.7	27
22	International comparison of peritoneal dialysis prescriptions from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Peritoneal Dialysis International, 2020, 40, 310-319.	2.3	27
23	Combination therapy with peritoneal dialysis and hemodialysis. Peritoneal Dialysis International, 2006, 26, 150-4.	2.3	26
24	Seventeen years' experience of surgical options for encapsulating peritoneal sclerosis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2011, 27, 53-8.	0.1	26
25	Surgical and Medical Treatments of Encapsulation Peritoneal Sclerosis. Contributions To Nephrology, 2012, 177, 38-47.	1.1	24
26	International Anemia Prevalence and Management in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2019, 39, 539-546.	2.3	24
27	Surgical Treatment for Encapsulating Peritoneal Sclerosis: 24 Years— Experience. Peritoneal Dialysis International, 2019, 39, 169-174.	2.3	22
28	Association between Dialysis Modality and Cardiovascular Diseases: A Comparison between Peritoneal Dialysis and Hemodialysis. Blood Purification, 2020, 49, 302-309.	1.8	22
29	Epidemiology of encapsulating peritoneal sclerosis in Japan. Peritoneal Dialysis International, 2005, 25 Suppl 4, S14-8.	2.3	22
30	Hypomagnesemia as a predictor of mortality in hemodialysis patients and the role of proton pump inhibitors: A cross-sectional, 1-year, retrospective cohort study. Hemodialysis International, 2016, 20, 580-588.	0.9	21
31	Cost-Effectiveness of Maintenance Hemodialysis in Japan. Therapeutic Apheresis and Dialysis, 2015, 19, 441-449.	0.9	19
32	Surgical treatment for encapsulating peritoneal sclerosis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2002, 18, 139-43.	0.1	17
33	The central dialysis fluid delivery system (CDDS): is it specialty in Japan?. Renal Replacement Therapy, 2016, 2, .	0.7	16
34	Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2008, 24, 51-5.	0.1	15
35	2011 JSDT Standard on the Management of Endotoxin Retentive Filter for Dialysis and Related Therapies. Therapeutic Apheresis and Dialysis, 2013, 17, 229-240.	0.9	14
36	Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Peritoneal Dialysis International, 2008, 28 Suppl 3, S205-10.	2.3	14

#	ARTICLE	IF	CITATIONS
37	Variation in Peritoneal Dialysis Time on Therapy by Country. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 861-871.	4.5	14
38	Five years' experience of combination therapy: peritoneal dialysis with hemodialysis. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2002, 18, 62-7.	0.1	13
39	Is There Enough Evidence to Prove That Hemodiafiltration Is Superior?. <i>Blood Purification</i> , 2018, 46, 3-6.	1.8	12
40	Mortality, hospitalization and transfer to haemodialysis and hybrid therapy, in Japanese peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2021, , 089686082110161.	2.3	12
41	Postoperative Day 1 Access Blood Flow and Resistive Index can Predict Patency in Distal Forearm Arteriovenous Fistula. <i>Journal of Vascular Access</i> , 2017, 18, 371-378.	0.9	11
42	Fully Automated Dialysis System Based on the Central Dialysis Fluid Delivery System. <i>Blood Purification</i> , 2009, 27, 56-63.	1.8	9
43	Umbilical Hernia in Peritoneal Dialysis Patients: Surgical Treatment and Risk Factors. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 606-610.	0.9	9
44	Markers in peritoneal effluent for withdrawal from peritoneal dialysis: multicenter prospective study in Japan. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2005, 21, 134-8.	0.1	9
45	Past and Present Perspectives on Encapsulating Peritoneal Sclerosis. <i>Contributions To Nephrology</i> , 2015, 185, 87-97.	1.1	8
46	Vasculopathy plays an important role during the development and relapse of encapsulating peritoneal sclerosis with conventional peritoneal dialysis solutions. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1519-1526.	0.7	8
47	Clinical effects of combined therapy with peritoneal dialysis and hemodialysis. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S126-9.	2.3	8
48	Encapsulating peritoneal sclerosis: prevention and treatment. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S289-92.	2.3	8
49	Impact of Hybrid Therapy Comprising Peritoneal Dialysis and Hemodialysis on Acute Cardiovascular Events. <i>Blood Purification</i> , 2019, 47, 330-336.	1.8	7
50	Questionnaire to nephrologists: Withdrawal from hemodialysis in a patient in the terminal stage of malignancy.. <i>Nihon Toseki Igakkai Zasshi</i> , 2003, 36, 1315-1326.	0.1	7
51	Development of online hemodiafiltration in Japan. <i>Renal Replacement Therapy</i> , 2021, 7, .	0.7	7
52	A case of encapsulating peritoneal sclerosis suspected to result from the use of icodextrin peritoneal solution. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2009, 25, 45-9.	0.1	7
53	Experience with the JMS Fully Automated Dialysis Machine. <i>ASAIO Journal</i> , 2003, 49, 547-553.	1.6	6
54	Effect of Predialysis Recombinant Human Erythropoietin on Early Survival After Hemodialysis Initiation in Patients With Chronic Kidney Disease: Coâ€¦ET Study. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 598-607.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Percutaneous Endoscopic Gastrostomy with Jejunal Extension for an Encapsulating Peritoneal Sclerosis Refractory to Surgical Enterolysis. <i>Peritoneal Dialysis International</i> , 2016, 36, 562-563.	2.3	6
56	Association between Dialysis Modality and Infectious Diseases: Peritoneal Dialysis versus Hemodialysis. <i>Blood Purification</i> , 2021, 50, 370-379.	1.8	6
57	Encapsulating peritoneal sclerosis-like findings in a hemodialysis patient without a history of peritoneal dialysis. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2003, 19, 176-9.	0.1	6
58	Prospective multicenter observational study of encapsulating peritoneal sclerosis with neutral dialysis solution--the NEXT-PD study. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2010, 26, 71-4.	0.1	6
59	Preferred Performance of the High-Performance Membrane in the Case of Online Hemodiafiltration. <i>Contributions To Nephrology</i> , 2011, 173, 36-43.	1.1	5
60	Efficacy of Intra-Arterial Treatment for Massive Gastrointestinal Bleeding in Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2014, 18, 24-30.	0.9	5
61	De Novo Renal Cell Carcinoma in a Kidney Allograft 20 Years after Transplant. <i>Case Reports in Transplantation</i> , 2015, 2015, 1-4.	0.3	5
62	<p>Health economic evaluation of peritoneal dialysis based on cost-effectiveness in Japan: a preliminary study</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 579-590.	1.9	5
63	On-Line Hemodiafiltration in Critical Care. <i>Therapeutic Apheresis and Dialysis</i> , 2002, 6, 199-203.	0.9	4
64	Complementary Dialysis for Daily Dialysis. <i>Blood Purification</i> , 2004, 22, 30-33.	1.8	4
65	On-line continuous hemodiafiltration in sepsis. <i>Transfusion and Apheresis Science</i> , 2006, 35, 265-269.	1.0	4
66	Terminology and Classification of Blood Purification in Critical Care in Japan. <i>Contributions To Nephrology</i> , 2010, 166, 11-20.	1.1	4
67	Vascular access in super-aged patients. <i>Journal of Vascular Access</i> , 2015, 16, S22-S27.	0.9	4
68	The impact of hemodialysis schedules on the day of the week of hospitalization for cardiovascular and infectious diseases, over a period of 20 years. <i>PLoS ONE</i> , 2017, 12, e0180577.	2.5	4
69	The efficacy of drug-eluting stent for recurrent central venous restenosis in a patient undergoing hemodialysis. <i>Journal of Vascular Access</i> , 2019, 20, 76-79.	0.9	4
70	International Icodextrin Use and association with peritoneal membrane function, fluid removal, patient and technique survival. <i>Kidney360</i> , 0, , 10.34067/KID.0006922021.	2.1	4
71	What Can We Expect from On-Line Hemodiafiltration?. <i>Blood Purification</i> , 2013, 35, 1-5.	1.8	3
72	A Clinical Significance of Intermittent Infusion Hemodiafiltration Using Backfiltration of Ultrapure Dialysis Fluid Compared to Hemodialysis: A Multicenter Randomized Controlled Crossover Trial. <i>Blood Purification</i> , 2019, 48, 368-381.	1.8	3

#	ARTICLE	IF	CITATIONS
73	Evaluation of dialysis dose during combination therapy with peritoneal dialysis and hemodialysis. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2007, 23, 135-9.	0.1	3
74	Fully Automated Dialysis System for Online Hemodiafiltration Built into the Central Dialysis Fluid Delivery System. <i>Contributions To Nephrology</i> , 2010, 168, 107-116.	1.1	2
75	Iliopsoas Abscess in Hemodialysis Patients With End-Stage Kidney Disease. <i>Therapeutic Apheresis and Dialysis</i> , 2019, 23, 534-541.	0.9	2
76	Combination therapy for COVID-19 in hemodialysis patients: Pharmacological treatments and renal replacement therapy based on the severity. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 475-477.	0.9	2
77	COVID-19-associated pulmonary aspergillosis in hemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 985-991.	2.9	2
78	Clinical Results of Daily Hemofiltration. <i>Blood Purification</i> , 2004, 22, 8-13.	1.8	1
79	A Role for the Asian Peritoneal Dialysis Community in Renal Replacement Therapy Worldwide. <i>Peritoneal Dialysis International</i> , 2008, 28, 9-11.	2.3	1
80	Intra-arterial Treatment for Massive Subcutaneous Hemorrhage in Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2014, 18, 284-290.	0.9	1
81	History and Development of Tsuchiya General Hospital in Hiroshima. <i>Blood Purification</i> , 2015, 40, I-V.	1.8	1
82	Effective Remedy for Encapsulating Peritoneal Sclerosis with Ureteroileal Fistula. <i>Peritoneal Dialysis International</i> , 2017, 37, 648-649.	2.3	1
83	Increased Frequency of In-Center Hemodialysis as Rescue Therapy: Impact on Hospitalization for Acute Cardiovascular Events. <i>Blood Purification</i> , 2019, 47, 377-384.	1.8	1
84	Vascular access management after percutaneous transluminal angioplasty using a calcium alginate sheet: a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1592-1596.	0.7	1
85	Perforative peritonitis confused with peritoneal dialysis-related peritonitis: Report of three cases. <i>International Journal of Surgery Case Reports</i> , 2020, 70, 20-23.	0.6	1
86	A case of sclerosing encapsulating peritonitis improved by surgical treatment subsequent to steroid therapy.. <i>Nihon Toseki Igakkai Zasshi</i> , 1999, 32, 1401-1405.	0.1	1
87	Penile calciphylaxis in patients with end-stage kidney disease undergoing dialysis: Invasive treatment and pain management. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 950-959.	0.9	1
88	SP435 VARIATION IN THE TREATMENT AND PREVENTION OF PERITONEAL DIALYSIS RELATED INFECTIONS: PRELIMINARY RESULTS FROM THE PERITONEAL DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (PDOPPS). <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i236-i237.	0.7	0
89	MP624 THE RISK OF HOSPITALIZATION OF DAY-OF-WEEK IN HD AND PD PATIENTS IN 20 YEARS OBSERVATION. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i549-i549.	0.7	0
90	Basal Cell Carcinoma Originating from a Skin Puncture Site above an Arteriovenous Fistula. <i>Journal of Vascular Access</i> , 2017, 18, e99-e100.	0.9	0

#	ARTICLE	IF	CITATIONS
91	P1195ASSESSMENT OF BODY FLUID VOLUME USING THE BIOIMPEDANCE METHOD IN PERITONEAL DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
92	MO680INTERNATIONAL COMPARISONS OF ICODEXTRIN PRESCRIPTION PRACTICE AND ITS ASSOCIATION WITH FLUID REMOVAL, BLOOD PRESSURE, PATIENT AND TECHNIQUE SURVIVAL*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
93	MO681PERITONEAL DIALYSIS TIME ON THERAPY AND REGIONAL DIFFERENCES IN DEATH, TRANSFER TO HEMODIALYSIS AND KIDNEY TRANSPLANTATION: RESULTS FROM THE PDOPPS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
94	FC 100ASSOCIATION OF SINGLE AND SERIAL MEASURES OF SERUM PHOSPHORUS WITH ADVERSE OUTCOMES IN PATIENTS ON PERITONEAL DIALYSIS: RESULTS FROM THE INTERNATIONAL PDOPPS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
95	Sclerosing encapsulating peritonitis after renal transplantation: A case report.. Nihon Toseki Igakkai Zasshi, 2001, 34, 1435-1439.	0.1	0
96	Evaluation of peritoneal damage by PD NAVI-characteristics of high transporter. Nihon Toseki Igakkai Zasshi, 2005, 38, 279-285.	0.1	0
97	Adequate dialysis and withdrawal in CAPD.. Nihon Toseki Igakkai Zasshi, 1994, 27, 1223-1228.	0.1	0
98	A case of advanced esophageal cancer in a chronic hemodialysis patient treated by mediastinoscopy and laparoscopy-assisted esophagectomy.. Nihon Toseki Igakkai Zasshi, 1997, 30, 1381-1385.	0.1	0
99	Comparison of prognosis between hemodialysis patients with acute multiple organ failure and patients with acute multiple organ failure alone.. Nihon Toseki Igakkai Zasshi, 1999, 32, 1391-1396.	0.1	0
100	MO716: A Different Pet Test: The Relationship between Pet Ownership and Peritonitis Risk in the Peritoneal Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0